Potential target antigens for a universal vaccine in epithelial ovarian cancer

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Nijman, Hans W ^a   Vermeij, Renee ^a   Daemen, Toos ^a   De Bock, Geertruida H ^a   De Graeff, Pauline ^a   Leffers, Ninke ^a   Lambeck, Annechien ^a   Ten Hoor, Klaske A ^a   Hollema, Harry ^a   Van Der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CANCER VACCINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NY ESO 1 ANTIGEN; PROTEIN P53; SP17 ANTIGEN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADOLESCENT; ADULT; AGED; ALPHA CHAIN; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; EPITHELIAL OVARY CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CARRIER PROTEINS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; MICROARRAY ANALYSIS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS; YOUNG ADULT;

EID: 77957874437     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/891505     Document Type: Article

References (68)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010. Ca: A Cancer Journal for Clinicians. In press
2. Holschneider C. H., Berek J. S., Ovarian cancer: epidemiology, biology, and prognostic factors Seminars in Surgical Oncology 2000 19 1 3 10
3. Bookman M. A., Standard treatment in advanced ovarian cancer in 2005: the state of the art International Journal of Gynecological Cancer 2005 15 6 212 220
4. Coilinson F., Jayson G., New therapeutic agents in ovarian cancer Current Opinion in Obstetrics and Gynecology 2009 21 1 44 53
5. Khong H. T., Restifo N. P., Natural selection of tumor variants in the generation of tumor escape phenotypes Nature Immunology 2002 3 11 999 1005
6. Kessler J. H., Melief C. J. M., Identification of T-cell epitopes for cancer immunotherapy Leukemia 2007 21 9 1859 1874
7. Svane I. M., Pedersen A. E., Nikolajsen K., Zocca M.-B., Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2 Vaccine 2008 26 36 4716 4724
8. Kuball J., Schuler M., Antunes Ferreira E., Herr W., Neumann M., Obenauer-Kutner L., Westreich L., Huber C., Wlfel T., Theobald M., Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man Gene Therapy 2002 9 13 833 843
9. Menon A. G., Kuppen P. J. K., van der Burg S. H., Offringa R., Bonnet M. C., Harinck B. I. J., Tollenaar R. A. E. M., Redeker A., Putter H., Moingeon P., Morreau H., Melief C. J. M., van de Velde C. J. H., Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients Cancer Gene Therapy 2003 10 7 509 517
10. Chaise C., Buchan S. L., Rice J., Marquet J., Rouard H., Kuentz M., Vittes G. E., Molinier-Frenkel V., Farcet J.-P., Stauss H. J., Delfau-Larue M.-H., Stevenson F. K., DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance Blood 2008 112 7 2956 2964
11. Tsuruma T., Iwayama Y., Ohmura T., Katsuramaki T., Hata F., Furuhata T., Yamaguchi K., Kimura Y., Torigoe T., Toyota N., Yagihashi A., Hirohashi Y., Asanuma H., Shimozawa K., Okazaki M., Mizushima Y., Nomura N., Sato N., Hirata K., Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer Journal of Translational Medicine 2008 6, article 24
12. Diefenbach C. S. M., Gnjatic S., Sabbatini P., Aghajanian C., Hensley M. L., Spriggs D. R., Lasonos A., Lee H., Dupont B., Pezzulli S., Jungbluth A. A., Old L. J., Dupont J., Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission Clinical Cancer Research 2008 14 9 2740 2748
13. Chianese-Bullock K.A., Lewis S. T., Sherman N. E., Shannon J. D., Slingluff Jr. C. L., Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies Vaccine 2009 27 11 1764 1770
14. Straughn J. M. Jr., Shaw D. R., Guerrero A., Bhoola S. M., Racelis A., Wang Z., Chiriva-Internati M., Grizzle W. E., Alvarez R. D., Lim S. H., Strong T. V., Expression of sperm protein 17 (Sp17) in ovarian cancer International Journal of Cancer 2004 108 6 805 811
15. Kirkwood J. M., Lee S., Moschos S., Albertini M. R., Michalak J. C., Sander C., Whiteside T., Butterfield L. H., Weiner L., Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFIN- 2b in advanced metastatic melanoma: eastern cooperative oncology group phase II trial E1696 Clinical Cancer Research 2009 15 4 1443 1451
16. Nijman H. W., Lambeck A., van der Burg S. H., van der Zee A. G. J., Daemen T., Immunologic aspect of ovarian cancer and p53 as tumor antigen Journal of Translational Medicine 2005 3, article 34
17. de Graeff P., Hall J., Crijns A. P. G., de Bock G. H., Paul J., Oien K. A., Ten Hoor K. A., de Jong S., Hollema H., Bartlett J. M. S., Brown R., van der Zee A. G. J., Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies British Journal of Cancer 2006 95 5 627 633
18. Lambeck A., Leffers N., Hoogeboom B.-N., Sluiter W., Hamming I., Klip H., Ten Hoor K., Esajas M., van Oven M., Drijfhout J.-W., Platteel I., Offringa R., Hollema H., Melief K., van der Burg S., van der Zee A., Daemen T., Nijman H., P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy International Journal of Cancer 2007 121 3 606 614
19. Chiriva-Internati M., Grizzi F., Weidanz A.J., Ferrari R., Yuefei Y., Velez B., Shearer M. H., Lowe D. B., Frezza E. E., Cobos E., Kast W. M., Kennedy R. C., A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17 Journal of Immunological Methods 2007 321 1-2 86 93
20. Nakazato T., Kanuma T., Tamura T., Faried L. S., Aoki H., Minegishi T., Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer International Journal of Gynecological Cancer 2007 17 2 426 432
21. Oka Y., Tsuboi A., Oji Y., Kawase I., Sugiyama H., WT1 peptide vaccine for the treatment of cancer Current Opinion in Immunology 2008 20 2 211 220
22. Li G., Zeng Y., Chen X., Larmonier N., Sepassi M., Graner M. W., Andreansky S., Brewer M. A., Katsanis E., Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro Clinical and Experimental Immunology 2007 148 1 136 145
23. Stauss H. J., Thomas S., Cesco-Gaspere M., Hart D. P., Xue S.-A., Holler A., King J., Wright G., Perro M., Pospori C., Morris E., WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells Blood Cells, Molecules, and Diseases 2008 40 1 113 116
24. Cohen C., Lohmann C. M., Cotsonis G., Lawson D., Santoianni R., Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis Modern Pathology 2003 16 6 574 583
25. Sui L., Dong Y., Ohno M., Watanabe Y., Sugimoto K., Tokuda M., Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors International Journal of Oncology 2002 21 2 315 320
26. Zaffaroni N., Pennati M., Colella G., Perego P., Supino R., Gatti L., Pilotti S., Zunino F., Daidone M. G., Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer Cellular and Molecular Life Sciences 2002 59 8 1406 1412
27. Matsuzaki J., Qian F., Luescher I., Lele S., Ritter G., Shrikant P. A., Gnjatic S., Old L. J., Odunsi K., Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1 Cancer Immunology, Immunotherapy 2008 57 8 1185 1195
28. Chen Y.-T., Hsu M., Lee P., Shin S. J., Mhawech-Fauceglia P., Odunsi K., Altorki N. K., Song C.-J., Jin B.-Q., Simpson A. J., Old L. J., Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer International Journal of Cancer 2009 124 12 2893 2898
29. Leffers N., Gooden M. J. M., Mokhova A. A., Kast W. M., Boezen H. M., ten Hoor K. A., Hollema H., Daemen T., van der Zee A. G. J., Nijman H. W., Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecologic Oncology 2009 113 2 256 263
30. Leffers N., Lambeck A. J. A., de Graeff P., Bijlsma A. Y., Daemen T., van der Zee A. G. J., Nijman H. W., Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation Gynecologic Oncology 2008 110 3 365 373
31. Cancer Committee of the International Federation of Gynaecology and Obstetrics. Staging announcement: FIGO Cancer Committee Gynecological Oncology 1986 25 383 385
32. Scully R. E., Histological typing of ovarian tumours World Health Organisation. International Histological Classification of Tumours 2004 Berlin, Germany Springer 11 19
33. Grizzi F., Gaetani P., Franceschini B., Di Ieva A., Colombo P., Ceva-Gremaldi G., Bollati A., Frezza E. E., Cobos E., Rodriguez y Baena R., Dioguardi N., Chiriva-Internati M., Sperm protein 17 is expressed in human nervous system tumours BMC Cancer 2006 6, article 23
34. Acs G., Pasha T., Zhang P. J., WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium International Journal of Gynecological Pathology 2004 23 2 110 118
35. Shimizu M., Toki T., Takagi Y., Konishi I., Fujii S., Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors International Journal of Gynecological Pathology 2000 19 2 158 163
36. Kleinberg L., Florenes V. A., Silins I., Haug K., Trope C. G., Nesland J. M., Davidson B., Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma Cancer 2007 109 2 228 238 (Pubitemid 46106237)
37. Ferrandina G., Legge F., Martinelli E., Ranelletti F. O., Zannoni G. F., Lauriola L., Gessi M., Gallotta V., Scambia G., Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters British Journal of Cancer 2005 92 2 271 277
38. Odunsi K., Jungbluth A. A., Stockert E., Qian F., Gnjatic S., Tammela J., Intengan M., Beck A., Keitz B., Santiago D., Williamson B., Scanlan M. J., Ritter G., Chen Y.-T., Driscoll D., Sood A., Lele S., Old L. J., NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer Cancer Research 2003 63 18 6076 6083
39. Jawhar N. M. T., Tissue microarray: a rapidly evolving diagnostic and research tool Annals of Saudi Medicine 2009 29 2 123 127
40. Chiriva-Internati M., Wang Z., Salati E., Timmins P., Lim S. H., Tumor vaccine for ovarian carcinoma targeting sperm protein 17 Cancer 2002 94 9 2447 2453
41. Barbolina M. V., Adley B. P., Shea L. D., Stack M. S., Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion Cancer 2008 112 7 1632 1641
42. Milne K., Barnes R. O., Girardin A., Mawer M. A., Nesslinger N. J., Ng A., Nielsen J. S., Sahota R., Tran E., Webb J. R., Wong M. Q., Wick D. A., Wray A., McMurtrie E., Kbel M., Kalloger S. E., Gilks C. B., Watson P. H., Nelson B. H., Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer PLoS ONE 2008 3 10, article e3409
43. Yakirevich E., Sabo E., Lavie O., Mazareb S., Spagnoli G. C., Resnick M. B., Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms Clinical Cancer Research 2003 9 17 6453 6460
44. Woloszynska-Read A., Mhawech-Fauceglia P., Yu J., Odunsi K., Karpf A. R., Intertumor and intratumor NY-ESO-1 expression heterogeneity Is associated With promoter-specific and global DNA methylation status in ovarian cancer Clinical Cancer Research 2008 14 11 3283 3290
45. Scanlan M. J., Gure A. O., Jungbluth A. A., Old L. J., Chen Y.-T., Cancer/testis antigens: an expanding family of targets for cancer immunotherapy Immunological Reviews 2002 188 22 32
46. de Graeff P., Crijns A. P. G., ten Hoor K. A., Klip H. G., Hollema H., Oien K., Bartlett J. M., Wisman G. B. A., de Bock G. H., de Vries E. G. E., De Jong S., van der Zee A. G. J., The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer British Journal of Cancer 2008 99 2 341 349
47. Seiden M. V., Burris H. A., Matulonis U., Hall J. B., Armstrong D. K., Speyer J., Weber J. D. A., Muggia F., A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies Gynecologic Oncology 2007 104 3 727 731
48. Lee C.-H., Huntsman D. G., Cheang M. C. U., Parker R. L., Brown L., Hoskins P., Miller D., Gilks C. B., Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma International Journal of Gynecological Pathology 2005 24 2 147 152
49. Milenic D. E., Wong K. J., Baidoo K. E., Ray G. L., Garmestani K., Williams M., Brechbiel M. W., Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications Cancer Biotherapy and Radiopharmaceuticals 2008 23 5 619 631
50. Horak E., Hartmann F., Garmestani K., Wu C., Brechbiel M., Gansow O. A., Landolfi N. F., Waldmann T. A., Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1 Journal of Nuclear Medicine 1997 38 12 1944 1950
51. Svane I. M., Pedersen A. E., Johnsen H. E., Nielsen D., Kamby C., Gaarsdal E., Nikolajsen K., Buus S., Claesson M. H., Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study Cancer Immunology, Immunotherapy 2004 53 7 633 641
52. Odunsi K., Qian F., Matsuzaki J., Mhawech-Fauceglia P., Andrews C., Hoffman E. W., Pan L., Ritter G., Villella J., Thomas B., Rodabaugh K., Lele S., Shrikant P., Old L. J., Gnjatic S., Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer Proceedings of the National Academy of Sciences of the United States of America 2007 104 31 12837 12842
53. Leffers N., Lambeck A. J. A., Gooden M. J. M., Hoogeboom B.-N., Wolf R., Hamming I. E., Hepkema B. G., Willemse P. H. B., Molmans B. H. W., Hollema H., Drijfhout J. W., Sluiter W. J., Valentijn A. R. P. M., Fathers L. M., Oostendorp J., Van Der Zee A. G. J., Melief C. J., Van Der Burg S. H., Daemen T., Nijman H. W., Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial International Journal of Cancer 2009 125 9 2104 2113
54. Galea-Lauri J., Wells J. W., Darling D., Harrison P., Farzaneh F., Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination Cancer Immunology, Immunotherapy 2004 53 11 963 977
55. Caspi R. R., Immunotherapy of autoimmunity and cancer: the penalty for success Nature Reviews Immunology 2008 8 12 970 976
56. Kirkwood J. M., Tarhini A. A., Panelli M. C., Moschos S. J., Zarour H. M., Butterfield L. H., Gogas H. J., Next generation of immunotherapy for melanoma Journal of Clinical Oncology 2008 26 20 3445 3455
57. Hwu P., Freedman R. S., The immunotherapy of patients with ovarian cancer Journal of Immunotherapy 2002 25 3 189 201
58. Glazyrin A. L., Kan-Mitchell J., Mitchell M. S., Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells Cancer Immunology, Immunotherapy 2003 52 3 171 178
59. Hung C.-F., Wu T. C., Monie A., Roden R., Antigen-specific immunotherapy of cervical and ovarian cancer Immunological Reviews 2008 222 1 43 69
60. Kim C. J., Dessureault S., Gabrilovich D., Reintgen D. S., Slingluff C. L. Jr., Immunotherapy for melanoma Cancer Control 2002 9 1 22 30
61. Cannon M. J., Santin A. D., O'Brien T. J., Immunological treatment of ovarian cancer Current Opinion in Obstetrics and Gynecology 2004 16 1 87 92
62. Kenter G. G., Welters M. J. P., Valentijn A. R. P. M., Lwik M. J. G., Berends-van Der Meer D. M. A., Vloon A. P. G., Drijfhout J. W., Wafelman A. R., Oostendorp J., Fleuren G. J., Offringa R., Van Der Burg S. H., Melief C. J. M., Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity Clinical Cancer Research 2008 14 1 169 177
63. Palmowski M. J., Choi E. M.-L., Hermans I. F., Gilbert S. C., Chen J.-L., Gileadi U., Salio M., Van Pel A., Man S., Bonin E., Liljestrom P., Dunbar P. R., Cerundolo V., Competition between CTL narrows the immune response induced by prime-boost vaccination protocols Journal of Immunology 2002 168 9 4391 4398
64. Hunder N. N., Wallen H., Cao J., Hendricks D. W., Reilly J. Z., Rodmyre R., Jungbluth A., Gnjatic S., Thompson J. A., Yee C., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1 The New England Journal of Medicine 2008 358 25 2698 2703
65. Doehn C., Esser N., Pauels H.-G., Kieig S. T., Stelljes M., Grossmann A., Jocham D., Drevs J., Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma European Urology 2009 56 1 123 133
66. Nie Y., Yang G.-Y., Song Y., Zhao X., So C., Liao J., Wang L.-D., Yang C. S., DNA hypermethylation is a mechanism for loss of expression of HLA class I genes in human esophageal squamous cell carcinomas Carcinogenesis 2001 22 10 1615 1623
67. Sers C., Kuner R., Falk C. S., Lund P., Sueltmann H., Braun M., Buness A., Ruschhaupt M., Conrad J., Mang-Fatehi S., Stelniec I., Krapfenbauer U., Poustka A., Schfer R., Down-regulation of HLA class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells International Journal of Cancer 2009 125 7 1626 1639
68. Serrano A., Tanzarella S., Lionello I., Mendez R., Traversari C., Ruiz-Cabello F., Garrido F., Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza- 2′ -deoxycytidine treatment International Journal of Cancer 2001 94 2 243 251 (Pubitemid 32911420)